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ABSTRACT   Common variable immunodeficiency (CVID) is one of the primary 
immunodeficiency. Regular immunoglobulin G (IgG) replacement therapy is often performed for 
patients with CVID. 
   We experienced a patient who was hospitalized in our hospital for repeated pneumonia and 
diagnosed CVID at the age of 10 years. He had often been absent from school due to infectious 
diseases. We were administered intravenous IgG (IVIG) two times and his serum level of IgG 
became over 1,000 mg/dL. Afterward, he was affected the hand-foot-and-mouth disease one 
week after discharge. At that time, his IgG level decreased to 751 mg/dL. To maintain stable 
IgG trough levels, we introduced subcutaneous IgG (SCIG). Since then, his IgG levels remained 
around 1,000 mg/dL, he has lived without suffering from infectious diseases. 
   There are some reports that IVIG and SCIG were compared and SCIG was able to obtain a 
stable IgG trough levels to prevent infection. In addition, because our patient is a mother and 
child family, it was difficult to visit the outpatient department frequently, so it was desirable to 
infuse at home. 
   We experienced a patient who had a stable trough levels with SCIG and improved quality of 
life, so we report this case with literature reviews.
 doi：10.11482/KMJ-E202046035　(Accepted on February 17, 2020)
Key words： Subcutaneous immunoglobulin,  Interavenous immunoglobulin,   
Common variable immunodeficiency,  Quality of life
〈Case Report〉
that are antibodies producing cells１）. CVID is one 
of the primary immunodeficiencies that are easily 
infectious due to antibodies production deficiency 
and repeat bacterial infections.
   CVID patients require regular immunoglobulin 
INTRODUCTION 
   Common variable immunodeficiency (CVID) is 
characterized by low levels of immunoglobulins, a 
lack of B mature lymphocytes especially memory 
B cells and/or a differentiation into plasma cells 
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dl, respectively. Because his immunoglobulin levels 
are low, he was first suspected of immunodeficiency 
and was referred to our hospital. 
   Laboratory data showed low serum antibody titers 
for specific pathogens despite of each vaccines 
(Table 1). Regarding T cells, the total number was 
1,961/μl, lymphocyte blastoid transformation by 
phytohemagglutinin was 42,200 cpm (control 302 
cpm), and there were no numerical or functional 
abnormalities. Fluorescence activated cell sorter 
using peripheral blood revealed CD19+CD20+ 
mature B cells were normal number (8.9%), and 
X-linked agammaglobulinemia was denied. IgD-
CD27+ swiched memory B cells were markedly 
decreased (1.7%), and he was diagnosed as CVID 
(Table 2). 
   Tazobactam/Piperacillin was administered by 
intravenous infusion, and IVIG (350 mg/kg) was 
administered on admission. Fever was reduced 
on the 2nd hospital day, and pneumoniae could 
be controlled. IVIG (350 mg/dl) was further 
administered aiming at IgG 1,000 mg/dl on the 3rd 
hospital day. His serum level of IgG was 1,269 mg/
dl at 4th hospital day (Fig. 1). 
   After discharge, He was scheduled to received 
IVIG infusion at 4 weeks interval but suffered from 
hand-foot-and-mouth disease. The IgG level at that 
G (IgG) replacement therapy to prevent infection 
for a lifetime２）. IgG replacement therapy has two 
routes of administration, intravenous (IVIG) and 
subcutaneous (SCIG) route. IVIG has problems 
such as difficulty of venous access, difficulty in 
obtaining stable IgG lebel and adverse events３）. 
   We experienced a patient with CVID suffered 
from hand-foot-mouth disease ,when IgG levels 
dropped from the peak to the trough after IVIG was 
introduced. We report that the patient subsequently 
swiched from IVIG to SCIG for obtaining stable 
IgG trough level and could prevent infection.
CASE REPORT
   A 10-year-old boy was referred to our hospital, 
because of prolonged fever and cough. He had 
experienced repeated otitis media, sinusitis and 
pneumonia since early childhood. Therefore, 
he had often been absent from school due to 
infectious diseases. He was never suspected of 
immunodeficiency because he did not have a family 
doctor. In addition, since he was a mother-child 
family and her mother worked, it was difficult to 
visit clinics frequently. At the age of 10 years, he 
was repeatedly afflicted with pneumonia and was 
often hospitalized in other hospital. His serum levels 
of IgG, IgA, IgM were <100 mg/dl, <6 mg/dl, 12 mg/
Table 1. Laboratory data
Peripheral blood Blood chemistry Virologic test
WBC 16,400 /μL CRP 8.27 mg/dL CMV IgG (EIA) 3.7
　Neut 74.7 % TP 6.2 g/dL EBV-EBNA-IgG (EIA) 0.2
　Lym 18.2 % Alb 4.0 g/dL VZV IgG (EIA) <2.0
RBC 535×104 /μL T-bil 0.5 mg/dL Mumps IgG (EIA) 8.7
Hb 13.5 g/dL AST 17 IU/L Meales IgG (EIA) <2.0
Ht 40.2 % ALT 12 IU/L Rubella IgG (EIA) <2.0
Plt 32.4×104 /μL LDH 163 IU/L
ALP 880 IU/L Sputum culture:
γ-GTP 15 IU/L 　Haemophilus influenzae
BUN 7 mg/dL Urine culture : 48 hour(-)
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time was 751 mg/dl. He had a prolonged fever for 
7 days and generalized vesicles. Stable serum IgG 
levels were necessary for prevent infection, and he 
was switched IgG replacement therapy from IVIG 
to SCIG. He received first SCIG infusion (85 mg/
kg) at hospital for safety confirmation followed 
by home-based SCIG infusion (115 mg/kg) at 
1week interval. Since then, the IgG trough level 
has remained around 1,000 mg/dl, and he has lived 
without serious infections (Fig. 1). 
   Genetic analysis using next generation sequencer 
revealed no causing gene mutations (ICOS, 
TNFRSF13B (TACI), TNFRSF13C (BEFF-R), 
CD19, MS4A1, CR2(CD21), CD81, IL21, NFKB1, 
NFKB2, IKZF1, MSN, PLCG2) of CVID.
DISCUSSION
   C V I D  i s  c h a r a c t e r i z e d  b y  l o w  l e v e l s 
o f  immunog lobu l in s ,  a  l ack  o f  B  ma tu re 
lymphocytes especially memory B cells and/or a 
differentiation into plasma cells that are antibodies 
producing cells１）. T cell dysfunction is exhibited 
in some patient. There were about two hundred 
patient with CVID reported by nationwide survey 
of Japan conducted in 2009４）. Because many 
patients with CVID develop after age 10 years, 
CVID occupies an important position as an adult 
form of immunodeficiency (average age is 20-30 
years old). Many patients with CVID have some 
symptoms by the age of 2-20 years and may be 
diagnosed in childhood like our patient. Patients 
with CVID experience recurrent bacterial infections 
Table 2. Immunological data
Pheripheral blood Flow cytometry
C3 169 mg/dL Lymph 2,800 /μL
C4 54 mg/dL CD3+ 1,624 /μL
CH50 >58.0 U/mL CD4+ 596 /μL
IgG <100 mg/dL
IgA <6 mg/dL CD4+CD45RA+ 14.1 %
IgM 12 mg/dL CD4+CD45RO+ 7.5 %
IgG2 <20 mg/dL CD19+ 8.9 %
IgE <1 mg/dL IgD+CD27- 84.6 %
PHA 42,200 CPM IgD+CD27+ 12.9 %
ConA 41,600 CPM IgD-CD27+ 1.7 %
PHA: lymphocyte blastoid transformation by phytohemagglutinin
ConA: lymphocyte blastoid transformation by ConcanavalinA
Fig. 1. clinical course : Transition of serum IgG trough levels
IgG: immunoglobulin G, IVIG: Intravenous immunoglobulin, SCIG: Subcutaneous immunoglobulin
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such as otitis media, sinusitis and pneumonia. 
Sinopulmonary infection are most commonly 
reported followed by gastrointentinal infection 
because of IgA deficiency５）. One third to a half 
of patients with CVID develop autoimmune 
disease or malignancy in their course. The causing 
genes identified include ICOS, TNFRSF13B 
(TACI), TNFRSF13C (BEFF-R), CD19, MS4A1, 
CR2(CD21), CD81, IL21, NFKB1, NFKB2, IKZF1, 
MSN, PLCG2. However, monogenic forms count 
for only 2-10% of patients with CVID６）. Causing 
gene was not identified in our patient either.
   Patients with CVID require IgG replacement 
therapy regularly to prevent infections and maintain 
for their lifetime２）. IVIG infusions every 3-4weeks 
are formerly standard practice in Japan, but 
developing systemic adverse effects of intravenous 
infusion and difficulty of obtaining venous access 
had been concerns in pediatric patients. In Japan, 
SCIG was introduced in 2013 later than other 
countries. Advantages of SCIG are no need of 
obtaining venous access, decreased systemic adverse 
effects and steady stable IgG trough level. Berger 
M reported that the difference between the peak 
and trough IgG level was 900 mg/dl for IVIG, 100 
mg/dl for SCIG. Adverse effects such as migraine 
and headache may be associated with rapid change 
of IgG levels for IVIG７）. Jolles S et al reported 
that switching the replacement therapy from IVIG 
to SCID could improve IgG levels without dose 
increases and prevented infection８）. Furthermore, 
there is a report that switching from IVIG to SCIG 
raised IgG trough levels and reduce days missed 
from work/school for infection treatment２，９）. In our 
case, the number of days missed from elementary 
school has decreased remarkably. Disadvantages 
of SCIG are frequency of administration weekly 
and necessity of acquiring skills of subcutaneous 
infusion by patient’s family. Since our patient is a 
mother-child family, it was difficult to have regular 
outpatient visits in a short period of time. In our 
case, home-visit nursing has been introduced as an 
aid to the family’s skill acquisition and assist with 
administration. 
   Cunningham-Rundles C reported baseline serum 
IgG trough level suggested to keep 600-900 mg/
dl to prevent infection in CVID10）. On the other 
hand, Orange JS reported that patients with primary 
immunodeficiency required more than 1,000 mg/dl 
IgG through level to prevent pneumonia11）. Because 
our patient had history of pneumonia, we managed 
to keep 1,000 mg/dl IgG through level.
   In conclusion, we experienced a pediatric patient 
who was diagnosed with CVID at 10 years old and 
introduced SCIG for prevent infection. Since SCIG 
is not necessary to obtain venous access and can be 
administered at home, it was considered useful in 
children like our case who have difficulty in visiting 
a clinic in a short period of time due to the home 
environment. 
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